Genelux Management
Management criteria checks 4/4
Genelux's CEO is Tom Zindrick, appointed in May 2014, has a tenure of 11.5 years. total yearly compensation is $1.47M, comprised of 40.4% salary and 59.6% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $456.75K. The average tenure of the management team and the board of directors is 2.3 years and 8 years respectively.
Key information
Tom Zindrick
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 40.39% |
| CEO tenure | 11.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
Feb 13
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
Oct 31We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate
Aug 24We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely
Jan 29We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate
Sep 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$32m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$30m |
| Dec 31 2024 | US$1m | US$595k | -US$30m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$27m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | US$6m | US$571k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$500k | US$500k | -US$5m |
| Sep 30 2022 | n/a | n/a | -US$5m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$517k | US$500k | -US$16m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$2m | US$519k | -US$14m |
Compensation vs Market: Tom's total compensation ($USD1.47M) is about average for companies of similar size in the US market ($USD1.55M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom Zindrick (66 yo)
Mr. Thomas D. Zindrick, also known as Tom, J.D., has been the Chief Executive Officer and President at Genelux Corporation since May 2014 and had been Chief Compliance Officer. Mr. Zindrick has been Execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.5yrs | US$1.47m | 0.24% $ 456.7k | |
| Chief Technical Officer | 2.3yrs | US$601.81k | 0.081% $ 151.4k | |
| CFO and Principal Financial & Accounting Officer | less than a year | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 2.3yrs | US$242.62k | 0.071% $ 133.0k | |
| Chief Medical Officer | 14.2yrs | no data | 0% $ 0 | |
| VP & Head of Regulatory Affairs | 2.3yrs | no data | 0.050% $ 93.0k |
Experienced Management: GNLX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.5yrs | US$1.47m | 0.24% $ 456.7k | |
| Lead Independent Director | 13.5yrs | US$225.00k | 0.12% $ 227.1k | |
| Non-Employee Independent Director | 23.2yrs | US$219.00k | 1.01% $ 1.9m | |
| Member of Clinical Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 2.2yrs | US$231.50k | 0.13% $ 249.1k | |
| Non-Employee Independent Director | 4.4yrs | US$215.50k | 0.14% $ 253.0k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
Experienced Board: GNLX's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 00:37 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genelux Corporation is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Emily Bodnar | H.C. Wainwright & Co. |